Galera Therapeutics
-
Malvern-based Galera Therapeutics to Be Acquired In Reverse Merger
Malvern-based Galera Therapeutics will be acquired by Obsidian Therapeutics in an all-stock reverse merger, writes John George for the Philadelphia Business Journal. The two companies have secured a $350 million private…
-
Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor
Doylestown-based Aprea Therapeutics has named Eugene Kennedy, MD, as chief medical advisor, adding a seasoned leader in oncology drug development to its executive team. Aprea…
-
Malvern-Based Galera Therapeutics Sells Drug Portfolio for Up to $105 Million
Following an FDA setback, Malvern-based Galera Therapeutics is selling its drug portfolio to the Canadian biotechnology firm Biossil in a deal that has been valued…
-
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway
Four months after its board of directors began dissolving the company, Galera Therapeutics secured a lifeline by acquiring Nova Pharmaceuticals, a privately held biotechnology firm,…
-
One Year After FDA Rejects Its Lead Candidate, Malvern-based Galera Therapeutics Moves to Dissolve
Malvern-based Galera Therapeutics is moving forward with a plan to shut down the company and liquidate all of its assets, writes John George for the…
-
Malvern-Based Galera Therapeutics Exploring Ways to Remain Afloat
Malvern-based Galera Therapeutics is continuing to explore alternatives that would allow it to persevere, writes John George for the Philadelphia Business Journal. Earlier this week,…
-
Malvern-based Galera Therapeutics Looks for Ways to Stay Afloat with Help from Third Party
After failing to convince the Food and Drug Administration that there is no need for additional testing for its lead new drug candidate, Malvern-based Galera…
-
Malvern-Based Biopharma Company Expects to Close $30 Million Direct Stock Offering
Malvern-based Galera Therapeutics is expecting to raise $30 million from a direct stock offering by the end of the week, writes John George for the…
-
As Stock Market Hits Low Point, These Chester County Companies Saw Their Stocks Drop the Most
At the start of the week, the stock market entered bear territory for the first time since 2020, further pushing down many local companies that…
-
Stock of Malvern-Based Biopharmaceutical Company Takes a Dive After Disappointing Trial for Its Lead Therapy
Malvern-based Galera Therapeutics’ stock fell by more than 70 percent after the biopharmaceutical firm announced that its cancer drug candidate did not meet its primary…
-
Malvern’s Galera Therapeutics in Line for $37.5 Million Payday
Malvern-based Galera Therapeutics recently triggered a $37.5 million payment by completing enrollment for a late-stage study of Avasopasem. John George reported on the new drug…
-
Malvern’s Galera Therapeutics Developing Solutions to Improve Treatment, Outcomes for Cancer Patients
Malvern-based Galera Therapeutics is developing solutions that are reducing the negative side effects of radiation therapy and helping to improve treatment and outcomes for cancer…
-
Buoyed by Drug to Fight Radiation Sickness in Cancer Patients, Malvern’s Galera Therapeutics Goes Public
At $12 a share, Malvern-based Galera Therapeutics raised $60 million in its initial public offering and is now trading under the GRTX symbol on the…
-
Chester County Briefly: March 9
Fox Rothschild The firm has announced that its Emerging Companies & Venture Capital practice group has been recognized in the 2018 Chambers USA guide in…
-
Chester County Briefly: December 2
Valley Forge Educational Services The Malvern-based Valley Forge Educational Services, which offers a continuum of school-year and summer educational programs and integrated clinical services, has…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
